A 6-month-old male infant from northern India presents with recurrent episodes of lethargy, vomiting, and developmental delay. Serum ammonia is 180 µmol/L (normal <50). Plasma amino acid analysis shows elevated glutamine and alanine. Urine organic acids are normal, and plasma citrulline is low. All of the following are consistent with the diagnosis EXCEPT:

Explanation

## Clinical Case: OTC Deficiency vs. CPS I Deficiency ### Case Summary - 6-month-old male with lethargy, vomiting, developmental delay - Serum ammonia: 180 µmol/L (severely elevated) - Elevated plasma glutamine and alanine (secondary to hyperammonemia) - Normal urine organic acids - **Low plasma citrulline** (key finding — indicates a block before citrulline formation) The clinical picture with **low citrulline** and **normal urine orotic acid** points to **CPS I deficiency**. However, if urine orotic acid were elevated, OTC deficiency would be the diagnosis. The question asks for the EXCEPT — the statement that is NOT consistent with the diagnosis. ### Analysis of Options **Option A — Inheritance Pattern (CORRECT — consistent with diagnosis):** - CPS I deficiency is **autosomal recessive**. However, **OTC deficiency** is **X-linked recessive**, making hemizygous males more severely affected than heterozygous females. - This statement describes X-linked dominant inheritance, which is incorrect for both CPS I and OTC deficiency. This is NOT consistent with either diagnosis → a candidate EXCEPT answer. **Option B — Enzyme Function (THE CORRECT "EXCEPT"):** - **Key Point:** The statement describes the condensation of carbamoyl phosphate and ornithine to form **carbamoyl ornithine** — this is the reaction catalyzed by **Ornithine Transcarbamylase (OTC)**, NOT CPS I. - CPS I catalyzes the formation of **carbamoyl phosphate** from NH₃ + CO₂ + 2 ATP (the first committed step of the urea cycle). - OTC then condenses carbamoyl phosphate with ornithine to form **citrulline** (not "carbamoyl ornithine" — citrulline is the correct product name, though carbamoyl ornithine is an intermediate name sometimes used). - Critically, this option attributes the OTC reaction to the defective enzyme in CPS I deficiency — this is factually **INCORRECT** and therefore NOT consistent with the diagnosis of CPS I deficiency. - **This is the EXCEPT answer.** **Option C — Mechanism of Hyperammonemia (CORRECT — consistent):** - **High-Yield:** CPS I is the rate-limiting enzyme that incorporates free ammonia into the urea cycle (first committed step). - Deficiency → ammonia cannot be incorporated → severe hyperammonemia. **Option D — Management (CORRECT — consistent):** - **Clinical Pearl:** Protein restriction reduces ammonia generation. Arginine or citrulline supplementation replenishes urea cycle intermediates, allowing some ammonia excretion via the remaining pathway. - Standard management for urea cycle disorders per Harrison's. ### Why Option B is the EXCEPT Option B describes the OTC reaction (condensation of carbamoyl phosphate + ornithine), NOT the CPS I reaction. In CPS I deficiency, the defective enzyme is CPS I (which makes carbamoyl phosphate), not OTC. Attributing the OTC reaction to the defective enzyme in this condition is factually inconsistent with the diagnosis. ### Differential Diagnosis: Urea Cycle Defects | Enzyme Defect | Inheritance | Plasma Citrulline | Urine Orotic Acid | Key Feature | |---|---|---|---|---| | CPS I | Autosomal recessive | ↓ Low | Normal | Ammonia cannot enter cycle | | OTC | X-linked recessive | ↓ Low | ↑↑ Elevated | Most common; orotic aciduria | | Argininosuccinate synthetase | Autosomal recessive | ↑↑ Elevated | Normal | Citrulline accumulates | | Argininosuccinate lyase | Autosomal recessive | Normal/↑ | Normal | Argininosuccinate in urine | | Arginase | Autosomal recessive | ↑↑ Elevated | Normal | Arginine accumulates | **Key Mnemonic:** Only OTC deficiency is X-linked; all others are autosomal recessive. [cite: Harrison 21e Ch 358; Robbins 10e Ch 7; KD Tripathi Essentials of Medical Pharmacology]